Skip to main content

Table 2 Associations between endothelial area, microvascular density and clinicopathological parameters in canine mammary carcinomas

From: Association of mast cell density, microvascular density and endothelial area with clinicopathological parameters and prognosis in canine mammary gland carcinomas

Clinicopathological parameters

Endothelial area (mean ± SD/1 mm2)

P

Microvascular density (mean ± SD/1 mm2)

P

Histological type (n = 134)

Carcinoma simple (n = 24)

2370.59 × 10–2 ± 546.39 µm

NS

115.68 ± 51.74

NS

Carcinoma solid (n = 19)

2632.44 × 10–2 ± 519.34 µm

 

81.94 ± 32.23

 

Comedocarcinoma (n = 9)

2787.11 × 10–2 ± 829.01 µm

 

89.79 ± 37.99

 

Carcinoma arising in a complex/mixed tumour (n = 3)

2549.33 × 10–2 ± 564.63 µm

 

51.32 ± 3.51

 

Carcinoma complex (n = 30)

2420.02 × 10–2 ± 569.64 µm

 

77.05 ± 32.69

 

Carcinoma mixed (n = 32)

2189.73 × 10–2 ± 438.96 µm

 

82.11 ± 37.58

 

Intraductal papillary carcinoma (n = 13)

2574.37 × 10–2 ± 492.51 µm

 

73.04 ± 30.42

 

Adenosquamous carcinoma (n = 4)

3100.95 × 10–2 ± 804.37 µm

 

118.25 ± 111.5

 

Histological grade (n = 13)

Grade I (n = 73)

2283.02 × 10–2 ± 516.64 µma

0.001

90.4 ± 44.12

NS

Grade II (n = 34)

2511.01 × 10–2 ± 526.49 µm

 

87.72 ± 48.73

 

Grade III (n = 27)

2820.39 × 10–2 ± 613.56 µma

 

78.86 ± 32.3

 

Tumour necrosis (n = 134)

Absent (n = 73)

2401.42 × 10–2 ± 581.02 µm

NS

80.96 ± 39.28

0.047

Present (n = 61)

2506.26 × 10–2 ± 567.85 µm

 

94.22 ± 46.96

 

Tumour-infiltrating

lymphocytes (n = 112)

Low (n = 55)

2447.44 × 10–2 ± 630.6 µm

NS

89.8 ± 46.99

NS

Moderate (n = 38)

2441.75 × 10–2 ± 556.49 µm

 

90.01 ± 39.22

 

High (n = 19)

2321 × 10–2 ± 484.13 µm

 

86.11 ± 50.37

 

Mitotic index (n = 134)

Low (n = 67)

2278.36 × 10–2 ± 534.91 µma

0.001

90.94 ± 49.05

NS

Moderate (n = 27)

2532.93 × 10–2 ± 465.75 µm

 

89.1 ± 41.01

 

High (n = 40)

2678.64 × 10–2 ± 625.2 µma

 

78.96 ± 33.21

 

Nuclear pleomorphism (n = 134)

Mild (n = 16)

2318.88 × 10–2 ± 483.38 µm

NS

85.34 ± 31.25

NS

Moderate (n = 82)

2397.22 × 10–2 ± 577.76 µm

 

57.74 ± 42.91

 

Marked (n = 36)

2625.31 × 10–2 ± 582.27 µm

 

86.02 ± 49.4

 

Tubular formation (n = 134)

Marked (n = 79)

2302.75 × 10–2 ± 519.61 µma

0.003

88.07 ± 44.42

NS

Moderate (n = 20)

2507.79 × 10–2 ± 513.41 µm

 

87.88 ± 32.17

 

Mild (n = 35)

2746.06 × 10–2 ± 574.39 µma

 

86.89 ± 43.28

 

Proliferation index (n = 134)

 ≤ 11% (n = 66)

2342.96 × 10–2 ± 576.48 µm

0.031

85.9 ± 48.4

NS

 > 11% (n = 67)

2557.68 × 10–2 ± 561.58 µm

 

88.74 ± 37.88

 

Tumour size (n = 45)

T1 < 3 cm (n = 11)

2129.6 × 10–2 ± 412.69 µm

NS

85.53 ± 62.2

NS

T2 3–5 cm (n = 10)

2611.14 × 10–2 ± 443.57 µm

 

84.08 ± 32.58

 

T3 > 5 cm (n = 24)

2472.56 × 10–2 ± 586.65 µm

 

90.53 ± 54.98

 

Lymph node metastasis (n = 45)

Yes (n = 10)

2440.42 × 10–2 ± 543.54 µm

NS

89 ± 51.06

NS

No (n = 35)

2374.24 × 10–2 ± 543.52 µm

 

82.13 ± 55.35

 
  1. Superscript letter denotes statistically significant differences between exact subgroups
  2. P statistical significance, NS not significant